Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins

Background: Cross-reactivity against human coronaviruses with Flebogamma® DIF and Gamunex®-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), S...

Descripción completa

Detalles Bibliográficos
Autores: Díez, José María, Romero, Carolina, Serra Gironella, Joan, Belló-Perez, Melissa, Rodon, Jordi, Honrubia, José Manuel, Segalés, Joaquim, Sola, Isabel, Enjuanes, Luis, Gajardo, Rodrigo
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:20.500.12327/1093
Acceso en línea:http://hdl.handle.net/20.500.12327/1093
https://doi.org/10.2217/imt-2020-0220
Access Level:acceso abierto
Palabra clave:619
id ES_3fcadf4730a75a992ecd2fbc3a55bb47
oai_identifier_str oai:recercat.cat:20.500.12327/1093
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulinsDíez, José MaríaRomero, CarolinaSerra Gironella, JoanBelló-Perez, MelissaRodon, JordiHonrubia, José ManuelSegalés, JoaquimSola, IsabelEnjuanes, LuisGajardo, Rodrigo619Background: Cross-reactivity against human coronaviruses with Flebogamma® DIF and Gamunex®-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: The tested IVIG contain antibodies with significant in vitro cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.info:eu-repo/semantics/publishedVersionFuture MedicineProducció AnimalSanitat Animal2020info:eu-repo/semantics/article9http://hdl.handle.net/20.500.12327/1093https://doi.org/10.2217/imt-2020-0220reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésImmunotherapyAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:20.500.12327/10932026-05-29T05:05:01Z
dc.title.none.fl_str_mv Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
title Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
spellingShingle Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
Díez, José María
619
title_short Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
title_full Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
title_fullStr Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
title_full_unstemmed Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
title_sort Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
dc.creator.none.fl_str_mv Díez, José María
Romero, Carolina
Serra Gironella, Joan
Belló-Perez, Melissa
Rodon, Jordi
Honrubia, José Manuel
Segalés, Joaquim
Sola, Isabel
Enjuanes, Luis
Gajardo, Rodrigo
author Díez, José María
author_facet Díez, José María
Romero, Carolina
Serra Gironella, Joan
Belló-Perez, Melissa
Rodon, Jordi
Honrubia, José Manuel
Segalés, Joaquim
Sola, Isabel
Enjuanes, Luis
Gajardo, Rodrigo
author_role author
author2 Romero, Carolina
Serra Gironella, Joan
Belló-Perez, Melissa
Rodon, Jordi
Honrubia, José Manuel
Segalés, Joaquim
Sola, Isabel
Enjuanes, Luis
Gajardo, Rodrigo
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Producció Animal
Sanitat Animal
dc.subject.none.fl_str_mv 619
topic 619
description Background: Cross-reactivity against human coronaviruses with Flebogamma® DIF and Gamunex®-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: The tested IVIG contain antibodies with significant in vitro cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12327/1093
https://doi.org/10.2217/imt-2020-0220
url http://hdl.handle.net/20.500.12327/1093
https://doi.org/10.2217/imt-2020-0220
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Immunotherapy
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9
dc.publisher.none.fl_str_mv Future Medicine
publisher.none.fl_str_mv Future Medicine
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406684837838848
score 15.811543

Similares en LA Referencia